United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Christopher Causey sold 2,240 shares of United Therapeutics stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the sale, the director now directly owns 4,185 shares of the company's stock, valued at $1,087,723.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Stock Performance
Shares of UTHR stock opened at $260.51 on Tuesday. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $264.85. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The company has a market cap of $11.56 billion, a P/E ratio of 12.32 and a beta of 0.54. The firm has a fifty day moving average price of $236.86 and a 200 day moving average price of $229.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business had revenue of $677.70 million during the quarter, compared to analysts' expectations of $620.31 million. During the same period in the prior year, the firm posted $4.86 EPS. The business's quarterly revenue was up 33.7% compared to the same quarter last year. Sell-side analysts predict that United Therapeutics Co. will post 23.88 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks
From Crypto 101 Media | Ad
Are you monitoring 13,217 cryptocurrencies everyday?
If not, you could miss the ONE that can make you wealthy beyond your wildest dreams.
You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls.
Claim your free seat by clicking here now.
UTHR has been the subject of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $300.00 target price on shares of United Therapeutics in a research report on Thursday, May 2nd. The Goldman Sachs Group upped their target price on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a "neutral" rating in a research note on Friday. Oppenheimer increased their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an "outperform" rating in a report on Thursday, May 2nd. Wedbush restated an "outperform" rating and issued a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, SVB Leerink assumed coverage on United Therapeutics in a research note on Monday, February 5th. They issued an "outperform" rating and a $330.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $308.78.
Check Out Our Latest Report on UTHR
Hedge Funds Weigh In On United Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. Blue Trust Inc. grew its position in shares of United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company's stock valued at $114,000 after buying an additional 46 shares during the last quarter. Formidable Asset Management LLC increased its position in shares of United Therapeutics by 1.5% during the third quarter. Formidable Asset Management LLC now owns 3,636 shares of the biotechnology company's stock worth $821,000 after purchasing an additional 53 shares in the last quarter. Alaska Permanent Fund Corp lifted its holdings in shares of United Therapeutics by 1.7% in the 3rd quarter. Alaska Permanent Fund Corp now owns 3,330 shares of the biotechnology company's stock valued at $752,000 after purchasing an additional 57 shares during the last quarter. MBM Wealth Consultants LLC lifted its holdings in shares of United Therapeutics by 2.7% in the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company's stock valued at $515,000 after purchasing an additional 59 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in United Therapeutics by 1.6% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company's stock worth $856,000 after buying an additional 61 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
